Evidence map›Paper›PMID 39251702›Full record

ArticleScientific reports2024

Immunologic mediators profile in COVID-19 convalescence.

Alexander Leonardo Silva-Junior, Lucas Silva Oliveira, Stephanny Dias, Thaina Cristina Cardoso Costa, Lilyane Amorim Xabregas, Fabíola Silva Alves-Hanna, Cláudia Maria Moura Abrahim, Walter Luiz Lima Neves, Myuki Alfaia Esashika Crispim, Diana Mota Toro and 15 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Alexander Leonardo Silva-JuniorPrograma de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
Lucas Silva OliveiraPrograma de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
Stephanny DiasDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Thaina Cristina Cardoso CostaDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Lilyane Amorim XabregasDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Fabíola Silva Alves-HannaDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Cláudia Maria Moura AbrahimDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Walter Luiz Lima NevesDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Myuki Alfaia Esashika CrispimDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Diana Mota ToroPrograma de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
Pedro Vieira Silva-NetoPrograma de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
Danielle Costa Marques AponteHospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil.
Tatiana Campos OliveiraHospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil.
Maria Carmo Costa SilvaRede Genômica em Saúde do Estado do Amazonas (REGESAM), Manaus, AM, Brazil.
Miharu Maguinoria Matsuura MatosHospital Universitário Getúlio Vargas (HUGV), Manaus, AM, Brazil.
Maria Perpétuo Socorro Sampaio CarvalhoDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Andrea Monteiro TarragôDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Nelson Abrahim FraijiDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil.
Lúcia Helena FaccioliFaculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.
Carlos Artério SorgiPrograma de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil.
Ester Cerdeira SabinoFaculdade de Medicina, Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Andrea Teixeira-CarvalhoGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, MG, Brazil.
Olindo Assis Martins-FilhoGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, MG, Brazil.
Allyson Guimarães CostaDepartamento de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil. allyson.gui.costa@gmail.com.
Adriana MalheiroPrograma de Pós-Graduação em Biotecnologia, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil. malheiroadriana@yahoo.com.br.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico PQ fellowshipsCoordenação de Aperfeiçoamento de Pessoal de Nível Superior PROCAD-Amazônia 2018 Program - #88881.200581/2018-01Fundação de Amparo à Pesquisa do Estado do Amazonas PCTI-EMERGESAÚDE/AM-Chamada II Program #006/2020Fundação de Amparo à Pesquisa do Estado do Amazonas POSGRAD Program #002/2023Fundação de Amparo à Pesquisa do Estado do Amazonas POSGRAD Program #002/2024Fundação de Amparo à Pesquisa do Estado do Amazonas Pró-Estado Program #002/2008Fundação de Amparo à Pesquisa do Estado do Amazonas Pró-Estado Program #005/2019Fundação de Amparo à Pesquisa do Estado do Amazonas Pró-Estado Program #007/2018
6 · The paper itself

Abstract

SARS-CoV-2 caused the pandemic situation experienced since the beginning of 2020, and many countries faced the rapid spread and severe form of the disease. Mechanisms of interaction between the virus and the host were observed during acute phase, but few data are available when related to immunity dynamics in convalescents. We conducted a longitudinal study, with 51 healthy donors and 62 COVID-19 convalescent patients, which these had a 2-month follow-up after symptoms recovery. Venous blood sample was obtained from all participants to measure blood count, subpopulations of monocytes, lymphocytes, natural killer cells and dendritic cells. Serum was used to measure cytokines, chemokines, growth factors, anti-N IgG and anti-S IgG/IgM antibodies. Statistic was performed by Kruskal-Wallis test, and linear regression with days post symptoms and antibody titers. All analysis had confidence interval of 95%. Less than 35% of convalescents were anti-S IgM+, while more than 80% were IgG+ in D30. Anti-N IgG decreased along time, with loss of seroreactivity of 13%. Eosinophil count played a distinct role on both antibodies during all study, and the convalescence was orchestrated by higher neutrophil-to-lymphocyte ratio and IL-15, but initial stages were marked by increase in myeloid DCs, B1 lymphocytes, inflammatory and patrolling monocytes, G-CSF and IL-2. Later convalescence seemed to change to cytotoxicity mediated by T lymphocytes, plasmacytoid DCs, VEGF, IL-9 and CXCL10. Anti-S IgG antibodies showed the longest perseverance and may be a better option for diagnosis. The inflammatory pattern is yet present on initial stage of convalescence, but quickly shifts to a reparative dynamic. Meanwhile eosinophils seem to play a role on anti-N levels in convalescence, although may not be the major causative agent. We must highlight the importance of immunological markers on acute clinical outcomes, but their comprehension to potentialize adaptive system must be explored to improve immunizations and further preventive policies.

Indexed as

Antibodies, ViralConvalescenceCOVID-19CytokinesImmunoglobulin GSARS-CoV-2AdultAgedEosinophilsFemaleHumansImmunoglobulin MLongitudinal StudiesMaleMiddle AgedAntibodies, ViralCytokinesImmunoglobulin GImmunoglobulin MAntibodyBrazilImmune hallmarksSevere acute respiratory syndrome (SARS)

Identifiers

PMID39251702
PMCPMC11384766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.